Can Ozempic, Mounjaro or Wegovy Reverse Fatty Liver?

Yes — for appropriate candidates. Semaglutide (the molecule in Ozempic and Wegovy) showed 62.9% MASH resolution at 72 weeks in the ESSENCE trial published in NEJM 2024. Reversal here means histological improvement on biopsy — resolution of steatohepatitis without worsening of fibrosis. Patients without significant alcohol use, with Type 2 diabetes or metabolic syndrome, and with sustained adherence to lifestyle change alongside the medication, are most likely to benefit.

In published trials, tirzepatide (Mounjaro) showed slightly higher rates of MASH resolution than semaglutide — 74% in SYNERGY-NASH vs 62.9% in ESSENCE. However, the two trials had different populations and durations, so direct comparison is imperfect. Tirzepatide is a dual GLP-1/GIP agonist with greater weight-loss magnitude (15–22% vs 14–17% for semaglutide). For severe MASH with high BMI, tirzepatide is often the stronger choice. For patients with primary T2D and moderate fatty liver, semaglutide is well established and often more affordable.

ALT and AST often start dropping within 4–12 weeks. Liver fat reduction on MRI-PDFF is measurable by 12–24 weeks. Histological MASH resolution typically requires 12+ months of sustained treatment. Fibrosis improvement (the longer-term goal) is slower still — often 18+ months. Rushing this is counterproductive. The trials that showed reversal ran for 52–72 weeks.

No, not in routine practice. Liver biopsy is the trial-grade reference standard but is not required clinically before initiating therapy. Ultrasound + FibroScan + the FIB-4 calculation from blood markers is sufficient for staging in most cases. Biopsy is reserved for unclear cases or when ruling out competing diagnoses.

No. Nirvana Clinic does not operate a permanent FibroScan machine. Dr. Manuj runs periodic FibroScan camps in partnership with imaging centres across Delhi NCR — typically once a month. Your initial booking includes scheduling for the next available camp where elastography-based staging is needed.

Yes — for fatty liver or obesity-related metabolic disease, where indicated. Wegovy (semaglutide 2.4mg) and Zepbound (tirzepatide) are licensed specifically for chronic weight management. Ozempic and Mounjaro are licensed in India for Type 2 diabetes but are prescribed off-label for obesity and metabolic disease when clinically appropriate. The prescribing decision is medical — based on disease, not just preference.

The terminology changed in 2023. The international consensus (AASLD, EASL, ALEH) replaced "NAFLD" (non-alcoholic fatty liver disease) with "MASLD" (metabolic dysfunction-associated steatotic liver disease) to reduce stigma and reflect the metabolic mechanism. Similarly, "NASH" (non-alcoholic steatohepatitis) became "MASH" (metabolic dysfunction-associated steatohepatitis). Same conditions — updated names. Most clinicians and trial literature now use the new MASLD/MASH terminology.

It can — and often does — without lifestyle changes embedded. Studies show partial regain of liver fat and body weight within 6–12 months of stopping if dietary patterns and activity levels return to baseline. This is why programme structure matters: medication is the catalyst; sustained behaviour change is the cure. Dr. Manuj's programme includes structured nutrition and activity guidance alongside the prescription.

The clinical thresholds are clear from published evidence: ≥5% body weight loss typically reduces liver fat; ≥7% loss can resolve steatohepatitis (MASH); ≥10% loss may reverse fibrosis. GLP-1 medications routinely produce 15–22% weight loss in 52 weeks of sustained use, which exceeds the threshold for fibrosis improvement — explaining why histological resolution is more achievable now than it was with diet-only approaches.

Initial assessments are in-person at Nirvana Clinic, Sun Twilight Mall — a proper history, examination, and lab review are essential before any GLP-1 prescription. Follow-up consultations (dose titration, side-effect management, lab review) are available by video for patients in Delhi NCR or further. NRI patients are seen in person on visits home and managed by video between visits.

Call or WhatsApp +91 88002 62767. Clinic location: Shop GF-93, Sun Twilight Mall, opposite Delta 1 Metro Station, Greater Noida 201308. Open Monday to Saturday, 9 AM to 8 PM. Same-day appointments often available. Email: [email protected]